Remainder of the Agreement. All services under Section 1 of the Agreement shall continue until such services are no longer rendered. All other provisions of the Agreement shall remain unchanged.
Remainder of the Agreement. Except as specifically set forth herein, all other provisions of the Agreement shall remain in full force and effect. Any items not herein defined shall have the meaning ascribed to them in the Agreement.
Remainder of the Agreement. All other provisions of the Agreement shall remain unchanged.
Remainder of the Agreement. Except as specifically set forth herein, all other provisions of the Sub-Administration Agreement shall remain in full force and effect. Any items not herein defined shall have the meaning ascribed to them in the Sub-Administration Agreement.
Remainder of the Agreement. Except as expressly modified hereby, all other terms and provisions of the Agreement shall remain in full force and effect, are incorporated herein by this reference, and shall govern the conduct of the parties hereto, provided, however, to the extent of any inconsistency between the provisions of the Agreement and the provisions of this Amendment, the provisions of this Amendment shall control.
Remainder of the Agreement any portion of the Agreement not so specifically amended in this Amendment shall remain the same. Nothing in this Amendment shall be construed as to limit any other section of the Agreement, PROVIDED THAT, any conflict between any section of the Agreement and this Amendment shall be construed so as this Amendment is the controlling document.
Remainder of the Agreement. Save as is expressly set out above or as necessarily implied by the context hereof, all other terms of the AGREEMENT shall remain of full force and effect. SIGNED at DURBAN, RSA on this 1ST day of April, 2008. XXXXXXX XXX XXXXXXXX, he warranting by his signature that he is duly authorized hereto SIGNED at PHILADELPHIA, PA on this 1ST day of April, 2008. XXXXXX XXXXXXXX, he warranting by his signature that he is duly authorised hereto *** This entire page has been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission. Should IROKO dispute the QUARTERLY LICENSE FEE, then the PARTIES shall enter into negotiations in good faith with regard -to agreeing the QUARTERLY LICENSE FEE or, failing such agreement within 10 (TEN) days after the commencement of such negotiation, either PARTY shall be entitled to refer the dispute/disagreement for determination by an Independent auditor appointed by agreement between the PARTIES, in writing, or falling such agreement within 5 (FIVE) days after either PARTY has required such referral, appointed by the President for the’ time being of the South African Institute of Chartered Accountants (or his successor-in-title) if IROKO requests such an appointment, or appointed by the then President of the Luxembourg lnstitut des Reviseurs d’Entreprises (or his successor-in-title), if ASPEN requests such an appointment Such auditor shall act as an expert and not as an arbitrator and his decision shall, save for any manifest error, be final and binding on the PARTIES. IROKO shall be entitled, at all reasonable times, either directly or through its duly authorised agents, to undertake an inspection and/or audit of all or any of ASPEN’S reports, books of account, manufacturing facilities and the like in an endeavour to verify that the QUARTERLY LICENSE FEE has been correctly calculated and ASPEN shall give IROKO and/or its duly agents, its full co-operation in this regard. The authorised agent or representatives of IROKO shall, however, prior to conducting any such inspection and/or audit, enter into a “confidentiality and lock-out agreement” in a form reasonably acceptable to ASPEN that would require the agent or representative to maintain confidentiality of the information obtained and desist from trading in the securities of ASPEN for a period specified therein. *** Portions of this page have been omitted pursuant to a request for confidential treatment and filed separa...
Remainder of the Agreement. Except as explicitly amended hereby, other provisions of the JVB Support Agreement (as otherwise amended, modified, supplemented or restated prior to the Effective Date) shall remain unchanged. For the avoidance of doubt, Article VI of the JVB Alliance Support Agreement shall continue in full force and effect except as expressly modified in the Master Agreement.
Remainder of the Agreement. Except as amended or modified by this Amendment, all other terms of the Agreement remain in full force and effect. If there is any discrepancy between a term as modified by this Amendment and the remaining terms of the Agreement, the resolution of the discrepancy shall be controlled by the terms of this Amendment.
Remainder of the Agreement. Save as expressly set out above or as necessarily implied by the context thereof all the other terms of the AGREEMENT shall remain of full force and effect. SIGNED by ASPEN at Mauritius on this 8th day of AUG 2011 For ASPEN GLOBAL INCORPORATED XXXXX XXXXXX, warranted by his signature that he is duly authorised hereto SIGNED by IROKO PHARMACEUTICALS, LLC at Philadelphia, PA USA on this 17th day of August 2011 For IROKO PHARMACEUTICALS, LLC Xxxxxx Xxxxxxxx, warranted by his signature that he is duly authorised hereto Commencing on January 1, 2011 and ending on June 30, 2011, the PRICE/S for the PRODUCTS will be as set forth in this Appendix 5. In addition, the PRICE/S for the PRODUCTS for the period commencing on July 1, 2011 and ending on June 30, 2012 are also set forth in this Appendix 5. During the term of this Agreement, these PRICES may be adjusted (i) after good-faith negotiations between the PARTIES and (ii) upon mutual agreement of the PARTIES in accordance with clause 7.4 of this AGREEMENT. 906502 ALDOMET 500 MG BULK (IROKO) [***] 906501 ALDOMET 250 MG BULK (IROKO) [***] 931801 INDOCID 25 MG CAPS BULK (IROKO) [***] 906502 ALDOMET 500 MG BULK (IROKO) [***] 906501 ALDOMET 250 MG BULK (IROKO) [***] 931801 INDOCID 25 MG CAPS BULK (IROKO) [***] *** Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission. EXECUTION VERSION 906502 ALDOMET 500 MG BULK TABS (IROKO) Methyldopa - Egis [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 906501 ALDOMET 250 MG BULK (IROKO) Methyldopa - Egis [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 931801 lNDOCID 25MG CAPS BULK (IROKO) Indomethacin (FIS) [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] Prices are based on actual confirmed API and Material Prices as at July 1st 2011 Prices exclude any freight or inflation assumptions [***] *** Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.
